These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 20812452

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).
    Myllylä V, Haapaniemi T, Kaakkola S, Kinnunen E, Hartikainen P, Nuutinen J, Rissanen A, Kuopio AM, Jolma T, Satomaa O, Heikkinen H.
    Acta Neurol Scand; 2006 Sep; 114(3):181-6. PubMed ID: 16911346
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H, Emre M.
    Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
    [Abstract] [Full Text] [Related]

  • 12. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
    Deleu D, Jacques M, Michotte Y, Ebinger G.
    Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV, Hoff J, Mouradian MM, Chase TN.
    Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
    [Abstract] [Full Text] [Related]

  • 16. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R, Lyons K, McGuire D, Silverstein P, Zwiebel F, Robischon M, Koller WC.
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA, Nelson MV, Berchou RC, Galloway MP, Kesaree N, Kareti D, Schlick P.
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [Abstract] [Full Text] [Related]

  • 19. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P, Fierro A, Reyes-Parada M, Sáez-Briones P.
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [Abstract] [Full Text] [Related]

  • 20. Perioperative medication withholding in patients with Parkinson's disease: a retrospective electronic health records review.
    Fagerlund K, Anderson LC, Gurvich O.
    Am J Nurs; 2013 Jan; 113(1):26-35; quiz 36. PubMed ID: 23247677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.